The Study
Phosphoenolpyruvate carboxykinase 2 activation of the AMPK–CEBPB axis to enhance glutamine utilization to promote glycolysis and malignant behavior in adenocarcinomas cells under glucose deprivation
This study is like watching a single robot in a lab and seeing that when you turn off one part, it stops moving. It doesn't prove that part causes the robot to move in all robots, or that it works the same way in real life. It just shows one possible way it might work inside that one robot.
Analysis score
Maximum 58 for a case-control study.
Where the score came from
When sugar is scarce, some lung cancer cells switch to using glutamine (a protein building block) for energy. They turn on a molecular chain reaction that opens a gate (SLC38A2) to suck in more glutamine, which helps them keep growing and spreading.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 548 / 100
Quality score
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this shows cancer cells have a backup energy plan when glucose is low, which could explain why some tumors resist treatments targeting sugar metabolism.
- 2Blocking the gate (SLC38A2) or the signal (AMPK or CEBPB) stopped cancer cells from using glutamine, reduced their energy (ATP), and slowed their growth and spread.
- 3Turning on AMPK or CEBPB brought back growth even when the starting signal (PCK2) was blocked.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Journal of Cell Communication and Signaling
Year
2026
Authors
Libo Ruan, Ke Xu, Wenjun Zeng, Ling Xiao, Minjun Zhao, Haiyan Zhang
Related Content
Claims (10)
In human lung cancer tissues, the levels of PCK2 and SLC38A2 proteins and messenger RNA are higher than in nearby non-cancerous lung tissue, and the levels of these two molecules increase together.
In lung cancer cells deprived of glucose, reducing the SLC38A2 protein decreases energy production, slows cell growth and movement, and increases cell death, showing that SLC38A2 is required for these cells to survive low-glucose conditions.
In human lung cancer cells deprived of glucose, AMPK activation is required to increase SLC38A2 expression, which supports greater use of glutamine and glycolysis, and reverses metabolic dysfunction caused by reduced PCK2 activity.
In lung cancer cells starved of glucose, higher levels of the PCK2 protein trigger a chain of molecular signals that increase the uptake and use of glutamine, boost sugar breakdown for energy, and cause the cells to multiply and spread more aggressively.
In human lung cancer tissues, the levels of two proteins, PCK2 and SLC38A2, are higher than in nearby healthy lung tissue, and the amounts of these two proteins increase together.
In lung cancer cells deprived of glucose, reducing AMPK activity decreases SLC38A2 expression, glutamine use, glycolysis, and cancer-like behaviors; activating AMPK restores these processes even when PCK2 is blocked, showing AMPK is required for PCK2 to control these metabolic functions.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.